3 research outputs found
THE THYMIDINE KINASE-1(TK-1) AS A POTENTIAL TUMOR MARKER: SERUM LEVELS IN SERUM OF PATIENTS WITH SOLID AND SYSTEM MALIGNANCE NEOPLASMS
The review summarizes the results of studies of levels and/or activity in the blood serum of a metabolic marker thymidine kinase-1 (TK-1) of proliferating cells in patients with lymphoproliferative diseases (LPD) and malignant neopasms (NM).Comparison of the data in the literature in some cases have been difficult due to the fundamentally different methods of detection the activity or concentration of TK-1, used by authors, even despite the presence of relatively high (but not absolute) correlation between these parameters (maximum 0.8).Many clinical and laboratory studies have shown levels of correlation and/or TK-1 activity with clinical stages and different types of LPD and solid MN and can serve as a prognostic factor for overall and recurrence-free survival of patients. When solid MN shown that the activity of TK-1 accurately reflects the proliferative status of tumor.A comparison of the dynamics of TC-1 in the process of chemotherapy and its clinical efficacy, different authors have received fundamentally different results: in some cases the marker reduction was associated with treatment efficacy, and in part of publications they show that the clinically relevant effects of the treatment observed increase in the marker after the first chemotherapy.The entire set of received data demonstrates the relevance of the further development of the algorithm use of TK-1 in oncology practice
Π’ΠΈΠΌΠΈΠ΄ΠΈΠ½ΠΊΠΈΠ½Π°Π·Π° 1 ΠΊΠ°ΠΊ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΠΉ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ ΠΌΠ°ΡΠΊΠ΅Ρ: ΡΡΡΡΠΊΡΡΡΠ°, ΡΡΠ½ΠΊΡΠΈΠΈ, Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π² Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΡ ΠΈ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΡ ΡΠΊΠ°Π½ΡΡ
In the review the role of the thymidine kinase (TK) to ensure the replication of DNA de novo and spare (salvage the) way in health and activateΒ alternate ways in carcinogenesis is described. The structure of cytoplasmic TK (TΠ-1), also called fetal, and the level of regulation of its activityΒ in the cells and their change during the cell cycle is described. Considering the data about the absence of TK-1 in resting (G0) cells, TK-1Β is positioned as a marker of proliferating cells, which activity is recorded from late G1 phase, peaking in S-phase, it is stored in the G2 and mitosis,Β quickly decreasing to undetectable levels in the early G1 phase.Β Data on the expression TK-1 (as compared with Ki-67 and PCNA (proliferating cell nuclear antigen)) in tumor tissues (colorectal, breast,Β cervical, lung, renal, prostate and ovarian cancer), as well as some benign and precancerous pathological processes in relation to the clinicalΒ and diagnostic features of these processes are systemized. These data suggest that the proliferative index studies on TK-1 (antibody to the domainΒ HRA-210) should be used together with Ki-67 and PCNA, for a more complete assessment of the proliferative status of malignant tumorsΒ and pre-cancerous and benign conditions, with the aim of prognosis of the tumor process and treatment planning.Π ΠΎΠ±Π·ΠΎΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ Π΄Π°Π½Π½ΡΠ΅ ΠΎ ΡΠΎΠ»ΠΈ ΡΠΈΠΌΠΈΠ΄ΠΈΠ½ΠΊΠΈΠ½Π°Π·Ρ (Π’Π) Π² ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΠΈ ΡΠ΅ΠΏΠ»ΠΈΠΊΠ°ΡΠΈΠΈ ΠΠΠ de novo ΠΈ ΠΏΠΎΡΡΠ΅Π΄ΡΡΠ²ΠΎΠΌ Π·Π°ΠΏΠ°ΡΠ½ΠΎΠ³ΠΎ (salvage)Β ΠΏΡΡΠΈ Π² Π½ΠΎΡΠΌΠ΅, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠΈ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ Π·Π°ΠΏΠ°ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΡΠΈ ΠΏΡΠΈ ΠΊΠ°Π½ΡΠ΅ΡΠΎΠ³Π΅Π½Π΅Π·Π΅. ΠΠΏΠΈΡΠ°Π½Ρ ΡΡΡΡΠΊΡΡΡΠ° ΡΠΈΡΠΎΠΏΠ»Π°Π·ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π’Π (Π’Π-1),Β Π½Π°Π·ΡΠ²Π°Π΅ΠΌΠΎΠΉ ΡΠ°ΠΊΠΆΠ΅ ΡΠ΅ΡΠ°Π»ΡΠ½ΠΎΠΉ, ΡΠ΅Π³ΡΠ»ΡΡΠΈΡ Π΅Π΅ ΡΡΠΎΠ²Π½Ρ ΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΈ ΠΈΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Π½Π° ΠΏΡΠΎΡΡΠΆΠ΅Π½ΠΈΠΈ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠΊΠ»Π°.Β Π‘ ΡΡΠ΅ΡΠΎΠΌ Π΄Π°Π½Π½ΡΡ
ΠΎΠ± ΠΎΡΡΡΡΡΡΠ²ΠΈΠΈ Π’Π-1 Π² ΠΏΠΎΠΊΠΎΡΡΠΈΡ
ΡΡ (G0) ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΎΠ½Π° ΠΏΠΎΠ·ΠΈΡΠΈΠΎΠ½ΠΈΡΡΠ΅ΡΡΡ Π² Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ΅ ΠΊΠ°ΠΊ ΠΌΠ°ΡΠΊΠ΅Ρ ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠΈΡΡΡΡΠΈΡ
Β ΠΊΠ»Π΅ΡΠΎΠΊ, Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ ΡΠ΅Π³ΠΈΡΡΡΠΈΡΡΠ΅ΡΡΡ, Π½Π°ΡΠΈΠ½Π°Ρ Ρ ΠΏΠΎΠ·Π΄Π½Π΅ΠΉ G1βΡΠ°Π·Ρ ΠΈ Π΄ΠΎΡΡΠΈΠ³Π°Ρ ΠΌΠ°ΠΊΡΠΈΠΌΡΠΌΠ° Π² S-ΡΠ°Π·Π΅, ΡΠΎΡ
ΡΠ°Π½ΡΠ΅ΡΡΡΒ Π² G2βΡΠ°Π·Π΅ ΠΈ ΠΌΠΈΡΠΎΠ·Π΅, Π±ΡΡΡΡΠΎ ΡΠ½ΠΈΠΆΠ°Π΅ΡΡΡ Π΄ΠΎ Π½Π΅ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅ΠΌΡΡ
Π·Π½Π°ΡΠ΅Π½ΠΈΠΉ Π² ΡΠ°Π½Π½Π΅ΠΉ G1βΡΠ°Π·Π΅.Β Π‘ΠΈΡΡΠ΅ΠΌΠ°ΡΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ Π΄Π°Π½Π½ΡΠ΅ ΠΎΠ± ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π’Π-1 (Π² ΡΠΎΠΏΠΎΡΡΠ°Π²Π»Π΅Π½ΠΈΠΈ Ρ Ki-67 ΠΈ PCNA (proliferating cell nuclear antigen)) Π² ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
Β ΡΠΊΠ°Π½ΡΡ
(ΠΏΡΠΈ ΠΊΠΎΠ»ΠΎΡΠ΅ΠΊΡΠ°Π»ΡΠ½ΠΎΠΌ ΡΠ°ΠΊΠ΅, ΡΠ°ΠΊΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ, Π»Π΅Π³ΠΊΠΎΠ³ΠΎ, ΠΏΠΎΡΠΊΠΈ, ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΡΠΈΡΠ½ΠΈΠΊΠΎΠ²),Β Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠΈ Π½Π΅ΠΊΠΎΡΠΎΡΡΡ
Π΄ΠΎΠ±ΡΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΠΈ ΠΏΡΠ΅Π΄ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ΅ΡΡΠ°Ρ
Π² ΡΠΎΠΏΠΎΡΡΠ°Π²Π»Π΅Π½ΠΈΠΈ Ρ ΠΈΡ
ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ. ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡ ΠΎ ΡΠΎΠΌ, ΡΡΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΈΠ½Π΄Π΅ΠΊΡΠ° ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠΈΒ ΠΏΠΎ Π’Π-1 (Ρ Π°Π½ΡΠΈΡΠ΅Π»Π°ΠΌΠΈ ΠΊ Π΄ΠΎΠΌΠ΅Π½Ρ XPA-210) ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡ Π½Π°ΡΡΠ΄Ρ Ρ Ki-67 ΠΈ PCNA Π΄Π»Ρ Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΠ»Π½ΠΎΠΉ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΡΠ°ΡΡΡΠ° Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠ΅Π΄ΡΠ°ΠΊΠΎΠ²ΡΡ
ΠΈ Π΄ΠΎΠ±ΡΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΡΠΎΡΡΠΎΡΠ½ΠΈΠΉ Π² ΡΠ΅Π»ΡΡ
ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° ΠΈ ΠΏΠ»Π°Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ°ΠΊΡΠΈΠΊΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ
Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΎ ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ ΠΌΠ°ΡΠΊΠ΅ΡΠ°Ρ ΠΈ ΠΈΡ ΠΌΠ΅ΡΡΠ΅ Π² ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ
The paper reviews modern concepts of serological tumor markers and their place in oncology: using for differential diagnostics, in the prognosisΒ of the tumor, follow-up and for preclinical revealing of relapses, as well as in the screening aimed at early detection of malignant neoplasms.Β Biochemical characteristics and functions of most informative tumor markers (CA125, PSA etc.) were described.Β Currently diagnostic indexes, obtained by the in vitro diagnostic multivariate index assay (IVDMIA), and algorithms using several serologicalΒ markers begin to apply in laboratory practice to increase diagnostic accuracy. Also some promising new serological tumor markers wereΒ described in this review.ΠΠ±Π·ΠΎΡ ΠΏΠΎΡΠ²ΡΡΠ΅Π½ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΡΠΌ ΠΎ ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠ°Ρ
(ΠΠ) ΠΈ ΠΈΡ
ΠΌΠ΅ΡΡΠ΅ Π² ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ:Β ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ Π΄Π»Ρ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ, Π² ΠΏΡΠΎΠ³Π½ΠΎΠ·Π΅ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ°, ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π΅ ΠΈ Π΄Π»Ρ Π΄ΠΎΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎΒ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΡΠ΅ΡΠΈΠ΄ΠΈΠ²ΠΎΠ² Π±ΠΎΠ»Π΅Π·Π½ΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ Π² ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π΅, Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΠΎΠΌ Π½Π° ΡΠ°Π½Π½Π΅Π΅ Π²ΡΡΠ²Π»Π΅Π½ΠΈΠ΅ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ. ΠΠΏΠΈΡΠ°Π½Ρ Π±ΠΈΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΈ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΡΡ
ΠΠ (Π‘Π125, ΠΠ‘Π ΠΈ Π΄Ρ).Β Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Ρ ΡΠ΅Π»ΡΡ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΠ½ΠΎΡΡΠΈ Π² Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅ Π½Π°ΡΠΈΠ½Π°ΡΡ ΠΏΡΠΈΠΌΠ΅Π½ΡΡΡΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΠ½Π΄Π΅ΠΊΡΡ, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΠΏΡΡΠ΅ΠΌ ΠΌΠ½ΠΎΠ³ΠΎΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° in vitro (in vitro diagnostic multivariate index assay, IVDMIA),Β ΠΈ Π°Π»Π³ΠΎΡΠΈΡΠΌΡ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΈΡ
ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ². Π’Π°ΠΊΠΆΠ΅ Π² ΠΎΠ±Π·ΠΎΡΠ΅ ΠΎΠΏΠΈΡΠ°Π½Ρ Π½Π΅ΠΊΠΎΡΠΎΡΡΠ΅ Π½ΠΎΠ²ΡΠ΅ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠ΅Β ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΠ